
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39251651
70987
10.1038/s41598-024-70987-2
Article
Gaze behavior in open-angle glaucoma patients during visuo-cognitive-motor tasks: a cross-sectional study
Freitag Constantin W. 1
Behrens Martin 2
Bielitzki Robert 1
Al-Nosairy Khaldoon O. 3
Stolle Francie H. 3
Prabhakaran Gokulraj T. 3
Beyer Rosalie 3
Thieme Hagen 3
Hoffmann Michael B. 34
Schega Lutz lutz.schega@ovgu.de

1
1 https://ror.org/00ggpsq73 grid.5807.a 0000 0001 1018 4307 Department of Sport Science, Institute III, Otto-von-Guericke University Magdeburg, Zschokkestraße 32, 39104 Magdeburg, Germany
2 grid.410722.2 0000 0001 0198 6180 University of Applied Sciences for Sport and Management Potsdam, Olympischer Weg 7, 14471 Potsdam, Germany
3 https://ror.org/03m04df46 grid.411559.d 0000 0000 9592 4695 Ophthalmic Department, University Hospital Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
4 Center for Behavioral Brain Research, Magdeburg, Germany
9 9 2024
9 9 2024
2024
14 2097815 2 2024
22 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This study investigated gaze behavior during visuo-cognitive-motor tasks with a change of movement direction in glaucoma patients and healthy controls. Nineteen glaucoma patients (10 females, 9 males) and 30 healthy sighted controls (17 females, 13 males) participated in this cross-sectional study. Participants performed two visuo-cognitive-motor tasks with a change of movement direction: (i) the “Speed-Court-Test” that involved stepping on different sensors in response to a visual sign displayed on either a large or small screen (165″ and 55″, respectively); (ii) the “Trail-Walking-Test” that required walking to 15 cones labeled with numbers (1–8) or letters (A-G) in an alternately ascending order. During these tasks, the time needed for completing each task was determined and the gaze behavior (e.g., saccade duration, fixation duration) was recorded via eye tracking. Data were analyzed with repeated measures analyses of covariance (ANCOVA; GROUP × SCREEN) and one-way ANCOVA. No differences between groups were found for the time needed to complete the tasks. However, during the “Trail-Walking-Test”, the fixation duration was longer for glaucoma patients than for controls (p = 0.016, ηp2 = 0.131). Furthermore, during the “Speed-Court-Test”, there was a screen size effect. Irrespective of group, saccade amplitudes were lower (p < 0.001, ηp2 = 0.242) and fixation durations were higher (p = 0.021, ηp2 = 0.125) for the small screen. Fixation durations were longer in glaucoma patients during the cognitively demanding “Trail-Walking-Test”, which might indicate a strategy to compensate for their visual impairment.

Subject terms

Diagnostic markers
Visual system
http://dx.doi.org/10.13039/501100001659 Deutsche Forschungsgemeinschaft 423926179 Otto-von-Guericke-Universität Magdeburg (3121)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Glaucoma belongs to a group of slowly progressing optic neuropathies1. It is considered the most common cause of irreversible blindness world wide2 with 76 million people affected in 2020 and forecasted to increase up to 111.8 million by 20403.

Glaucoma is characterized by a thinning of the retinal ganglion cell layer due to axonal degeneration of the retinal ganglion cells4. It usually leads to peripheral visual field loss, which is almost unnoticeable in the early stages of glaucoma5, but its extent increases with disease duration1,3, 6. The retinal ganglion cell decay affects great parts of the post-retinal visual system including subcortical regions4,7, 8. Preperimetric glaucoma patients have been shown to exhibit altered patterns of saccadic eye movements in comparison to healthy sighted controls9, with a probable involvement of cortical and subcortical structures8 including those related to the control of saccadic eye movements10. Consequently, alterations of saccadic eye movements might serve as a biomarker for altered subcortical retinal projections11.

These glaucoma-induced changes might impair activities of daily living, such as reading, walking, and driving11,12. However, studies addressing the gaze behavior of glaucoma patients reported heterogenous results13,14. Very few previous studies have assessed gaze behavior in glaucoma patients in comparison to healthy sighted controls while walking through an environment depicting a real-world condition to examine potential compensatory strategies during activities of daily living11,15. In a real-life shopping task16, the authors reported that glaucoma patients glanced frequently towards their visual defect area16. Furthermore, Cheong et al. conducted a real-life street crossing task13 and reported a reduced fixation area and a different fixation distribution in the glaucoma patients compared with the healthy sighted controls, which is in contrast to Geruschat et al.17, who failed to find differences in the number of fixations between glaucoma patients and healthy sighted controls. However, these differences might be related to the different tasks (no street crossing13 vs. street crossing17 street crossing). In another study by Lajoie et al. glaucoma patients and healthy sighted controls walked through an obstacle navigation course during single- and dual-task conditions, respectively18. The authors demonstrated increased fixation durations and fixation counts for the single-task condition in glaucoma patients18. Nevertheless, none of these studies recorded gaze behavior during visuo-cognitive-motor tasks that require walking with a change of movement direction.

In addition to visual deficits, it has previously been discussed that glaucoma might also be related to cognitive impairments19. Therefore, the present study aimed to investigate differences in execution time and gaze behavior during two different visuo-cognitive-motor tasks between glaucoma patients and healthy sighted controls. For this purpose, the interactive Speed Court® system (GlobalSpeed GmbH, Hemsbach, Germany)20,21, here referred to as “Speed-Court-Test” (primary outcome), and the “Trail-Walking-Test”22 (secondary outcome) were used to examine gaze behavior, cognitive performance, and functional mobility. These tasks demand gaze shifts to (“Speed-Court-Test”) or search for a visual target (“Trail-Walking-Test”), making a visual stimulus-dependent decision, and a corresponding motor action with a change of movement direction.

It was hypothesized that (i) glaucoma patients have longer execution times during the “Speed-Court-Test” and the “Trail-Walking-Test” compared to healthy sighted controls. Moreover, based on the study by Lajoie et al.18, it was assumed that (ii) glaucoma patients have longer fixation durations18 compared to healthy sighted controls during the “Speed-Court-Test” and the “Trail Walking-Test”.

Methods

Study design

In this article, the presented data were recorded during the baseline measurements of a longitudinal study examining the effects of a multimodal vs. unimodal exercise intervention on visual, motor, and cognitive performance measures as well as structural and functional brain adaptations in glaucoma patients and healthy sighted control participants (German Clinical Trial Register, ID: DRKS00022519/05.08.2020, https://drks.de/search/de/trial/DRKS00022519). The study was approved by the Ethics Committee of the University Medical Faculty Magdeburg (32/18) and performed in accordance with the tenets of the Declaration of Helsinki. All participants signed the informed consent form before participating in this study.

Participants

A sample size calculation for a repeated measures analysis of variance (ANOVA) with two groups (GROUP: glaucoma patients, healthy sighted controls) and two conditions (small screen and large screen) for the “Speed-Court-Test” was performed with G*Power (version 3.1)23. The following input variables were used: medium effect size (f = 0.25), a significance level of 0.05 with a power of 0.95 and correlation among the repeated measures of 0.7. According to the calculation, a total sample size of 34 participants (17 participants per group) was required.

All glaucoma and healthy sighted participants underwent standard ophthalmological examination including best corrected visual acuity (BCVA) and visual field (VF), and optical coherence tomography (OCT). For BCVA testing, early treatment of diabetic retinopathy standard (ETDRS) charts were used. For VF testing, standard automated perimetry employing the Swedish Interactive Threshold Algorithm 24-2 protocol (SITA-Fast) of the Humphrey Field Analyzer 3 (Carl Zeiss Meditec AG, Jena, Germany) was used for testing each eye separately. For binocular VF testing, a 24-2 binocular VF testing was conducted using the Ocusweep™ Perimeter (Ocusweep SAP, Ocuspecto Ltd, Turku, Finland). Ocusweep perimeter enabled VF testing without head or chin rest under ambient light conditions. For both VF tests, the mean deviation (MD [dB]) from a control cohort was determined for VF sensitivity assessment, where negative values indicate greater VF loss. For structural data assessment, OCT scans were acquired using a spectral domain OCT device employing Glaucoma Module Premium edition (Heidelberg Spectralis®, Heidelberg Engineering, Heidelberg, Germany) to estimate peripapillary retinal nerve fiber layer thickness (pRNFL) of each eye. After ophthalmological examination, glaucoma was defined as follows: (i) optic disc cupping with a vertical cup-to-disc ratio ≥ 0.7, (ii) retinal fiber layer defect and/or a local notching of the optic disc rim, and/or (iii) characteristic glaucomatous VF defects. All patients were on IOP-lowering medication.

The recruitment of the participants took place at the Department of Ophthalmology at the University Hospital Magdeburg, via local ophthalmologists and national patient networks. The following inclusion criteria were applied: (i) ≥ 60 years, (ii) diagnosis of open-angle glaucoma (only for the glaucoma group), (iii) BCVA ≥ 0.8 decimal unless glaucoma-related in the OAG group, (iv) normal visual function parameters unless glaucoma-related, (v) no other conditions affecting visual function, and (vi) ability to walk at least 6 min without walking support. The exclusion criteria were as follows: (i) any eye disease affecting the visual acuity or VF estimates of visual function (e.g., cataract [except incipient stage], ocular trauma history and ocular surgeries [except glaucoma or cataract surgery]), (ii) neurological diseases, and (iii) conditions that limit the physical performance of the participants (orthopedic diseases including arthrosis (grade II or higher), musculoskeletal impairments, tendinitis, tenosynovitis, myositis, prosthesis in the lower extremities, joint replacements, neurological disorders, rheumatism, cardiovascular disorders, stroke, and/or heart-rate related disease).

Overall, 49 participants, 19 with glaucoma (glaucoma group: 9 males, 10 females, [mean ± standard deviation], age 71 ± 6 years, height 168.7 ± 8.5 cm, body mass 73.0 ± 16.7 kg) and 30 age-matched healthy sighted participants (control group: 13 males, 17 females, age 71 ± 5 years, height 168.3 ± 10.4 cm, body mass 75.3 ± 17.8 kg) were included in this study (see Table 1 for ophthalmological details). Table 1 Ophthalmological characteristics of the participants.

	Controls
(n = 30)	Glaucoma
(n = 19)	Difference	
Median|range	Median|range	p-value	
MD_right	0.59|5.09	− 0.67|25.97	0.015	
MD_left	0.15|5.92	− 1.09|22.00	0.009	
MD_binocular	0.70|3.3	− 0.40|9.6	 < 0.001	
	Mean ± SD	mean ± SD	p-value	
BCVA	− 0.11 ± 0.08	− 0.07 ± 0.13	0.236	
pRNFL_right	91 ± 12.29	77 ± 12.71	 < 0.001	
pRNFL_left	89 ± 10.81	76 ± 14.94	 < 0.001	
IOP_right	15.7 ± 2.8	16.9 ± 5.9	0.435	
IOP_left	16.5 ± 3.8	16.9 ± 6.1	0.773	
SE_binocular	0.8 ± 1.5	0.2 ± 1.8	0.227	
BCVA: best corrected visual acuity [logMAR], pRNFL_right/left: peripapillary retinal nerve fiber layer (pRNFL) thickness [µm], MD_right/left: mean deviation [dB], IOP: intraocular pressure, SE: spherical equivalent,SD: standard deviation.

General procedure

Over a period of two consecutive days (at the same time of day), the participants performed several tests including single- and dual-task gait analyses and two visuo-cognitive-motor tasks: the “Speed Court-Test” and the “Trail-Walking-Test”22.

At the beginning of day one, each participant underwent the following procedure: (i) signing the informed consent, (ii) documenting their physical activity with the German version of the Freiburger Questionnaire on Physical activity24, (iii) measuring anthropometric data, (iv) assessing static postural control using the MFT S3 check (MFT Bodyteamwork GmbH, Kirchberg, Austria)25, (v) single-task walking, (vi) dual-task walking, and (vii) visuo-cognitive-motor task performance. On day two, the participants underwent the following procedure: (i) single-task walking, (ii) dual-task walking and (iii) visuo-cognitive-motor task. The visuo-cognitive-motor tasks and the dual-task gait test were conducted in a randomized order. In this regard, one of the visuo-cognitive-motor tasks was performed on the first day and the other on the second day. Due to the COVID-19 pandemic, participants were instructed to wear an FFP2 mask during all laboratory visits.

Gaze behavior data

Participants were equipped with mobile binocular eye tracking glasses (Senso-Motoric Instruments, SMI ETG 2, Teltow, Germany, resolution of 1280 × 960 pixels, sampling frequency of 60 Hz). The eye tracker's gaze position accuracy was indicated by the manufacturer to be of 0.5°26. Precision values of the mobile system were not provided by the manufacturer. Pastel26 and Hooge27 reported precision values ranging from 0.03° to 0.32°. A Samsung Galaxy S4 Smartphone (Samsung, Seoul, South Corea, 1.7 GHz processor) with the iView ETG Software (Senso-Motoric Instruments, Teltow, Germany) was used to record the data for later analysis. At the beginning of each measurement session, an instant cursor three-point calibration was conducted according to the manufacturer’s calibration protocol. To compensate for refractive error, the mobile eye tracker was equipped with lenses matching the spherical equivalent of refractive correction when required. The recorded data were analyzed with the BeGaze software, using the SMI Event Detection algorithm (Senso-Motoric Instruments, Version 3.7.40, Teltow, Germany). Eye-tracking data before the start and after the end of the visuo-cognitive-motor tasks were excluded. Outcome variables of interest were performance (s), saccade duration (ms), saccade frequency (saccades/s), saccade amplitude (°), fixation duration (ms), fixation frequency (fixations/s).

Visuo-cognitive-motor tasks

The visuo-cognitive-motor tasks included the “Speed-Court-Test” and “Trail-Walking-Test”22.

The “Speed-Court-Test” was conducted using the interactive system Speed Court® (GlobalSpeed GmbH, Hemsbach, Germany)20. In the context of the present study, Speed-Court was used to assess cognitive flexibility28 and functional mobility. The Speed Court® System consists of an area (5 × 5 m) with 12 sensor plates placed on the floor, which are connected to a computer. Using the manufacturers software, the sensors can be displayed on a screen and the participants had to step on specific sensors depending on which was shown on the screen (see Fig. 1). One test trial included 36 randomized colored (white, blue, black) stimuli, which were shown on a display wall consisting of 9 monitors, three per row (55″ screen size, resolution of 1920 × 1080 pixel, respectively). Each color was assigned to a specific task: (i) white stimulus: participant had to go the displayed sensor plate; (ii) blue stimulus: participant had to go to sensor plate 11, and (iii) black stimulus: participant had to go to the opposite sensor plate (see Fig. 1). After the presentation of each stimulus, the participants had to go to the center plate before the next stimulus was presented. The test included two screen conditions (see Fig. 1): (i) large screen, 165″ (height: 205.2 cm, width: 364.2 cm) and (ii) small screen, 55″ (height: 68.4 cm, width: 121.4 cm, center monitor of the display wall), which the participants had to perform three times in a randomized order, respectively. Approximate minimal and maximal viewing distances were 1 m and 5.5 m, respectively. The participants performed one familiarization trial for each screen condition, followed by the experimental trials. The starting position was behind the center sensor plate with the eyes directed to the display wall. The participants triggered the 3-s countdown for the start of the test by tipping on the center sensor plate. The time to accomplish the task (“performance”) and the eye tracking data of the fastest trial for each screen condition (large screen and small screen condition) were analyzed.Fig. 1 Experimental set-up of the “Speed-Court-Test”, condition small screen (A). Explanation of the color specific stimuli: white stimulus, participant had to go the displayed sensor plate (B); blue stimulus, participant had to go to sensor plate 11 (C); black stimulus, participant had to go to the opposite sensor plate (D).

The participants conducted the modified “Trail-Walking-Test” (third condition of the Trail-Walking-Test by Schott22) to asses working memory, cognitive flexibility, and functional mobility. The investigator positioned 15 cones, labeled with numbers or letters, on a 5 × 5 m large area. Each cone, depending on the number (1 to 8) or letter (A to G) had a designated fixed position (see Fig. 2). The participants were instructed to walk towards the cones in an alternately ascending order (1, A, 2, B, 3, C and so on) as fast as possible and safe as possible (without running). They had to touch each cone with one foot to signal the decision to the instructor before walking to the next cone. If the wrong cone was selected (e.g., 2, C), the investigator indicated: “STOP, please go back to the last cone”. The starting position was next to the cone with the number 1. After the start signal, the time was recorded until the cone with the number 8 was touched. The participants performed the modified “Trail-Walking-Test” three times and the time required to accomplish the task, i.e. performance, as well as the eye tracking data of the fastest trial were used for analyses.Fig. 2 Experimental set-up of the “Trail-Walking-Test”. The participants had to walk towards the cones in an alternately ascending order (1, A, 2, B, 3, C and so on).

Statistical analysis

Data were analyzed using the Statistical Package for Social Science (SPSS® Statistics Version 28.0, IBM® Corp., New York, USA). Normal distribution was checked using the Shapiro–Wilk test. Since previous studies have shown the repeated measures ANCOVA and independent t-tests to be robust against moderate violation of normality29–31, nonparametric tests were not used to check for differences. Differences were considered significant when p ≤ 0.05.

Differences between the groups in the anthropometric data were checked with independent t-tests. To analyze the data recorded during the “Speed-Court-Test”, a two-way repeated measures ANCOVA with the between-subject factor GROUP (glaucoma patients versus healthy sighted controls) and within-subject factor SCREEN (large screen and small screen condition) was performed to compare the data of groups. Differences between groups regarding the data recorded during the “Trail-Walking-Test” were checked using a one-way ANCOVA. Given that the number of males and females differed between groups, sex was used as covariate. In case of significant main or interaction effects, Bonferroni-corrected post-hoc tests were conducted. Data are presented as means ± standard deviations and mean differences with 95% confidence intervals (CI). The effect size partial eta squared (ηp2) was calculated for the ANCOVA and was interpreted according to Lakens32: small (ηp2 ≥ 0.01), medium (ηp2 ≥ 0.06), and large effect (ηp2 ≥ 0.14). Additionally, if main effects were detected, a secondary analysis (two-way repeated measures ANCOVA or one-way ANCOVA) excluding partcipants with adavanced  glaucoma was conducted to check if the severity of the glaucoma stage has an impact on the present results.

Further, correlations between gaze behavior, visuo-cognitive motor task performance and visual performance in glaucoma patients were examined. For normal distributed data, the Pearson correlation or for non-normal distributed data the Spearman correlations coefficient was used. The correlations coefficients were interpreted according Cohen33: small (r ≥ 0.1), medium (r ≥ 0.3), and large (r ≥ 0.5). Due to the explorative nature of the analysis in the present study, no correction for multiple testing was applied.

Results

Due to invalid data and drop-outs, data of nine participants (six of the control group and three of the glaucoma group) were not completely included in the analyses. Furthermore, 2 participants with advanced glaucoma were excluded only for the secondary analysis. To increase transparency, the number of analyzed cases for the respective parameter is shown in Tables 2, 3. An overview of all parameters including the p-values and effect sizes is presented Tables 2, 3 and in Fig. 3. Table 2 Means ± standard deviations of the eye tracking data during the “Speed-Court-Test” of glaucoma patients and healthy sighted controls as well as the outcomes of the ANCOVA.

Condition	Large Screen	Small Screen	Repeated Measures ANCOVA	
Screen	Group	Screen × Group	
Performance (s)	
 Control

N = 27

	91.590

 ± 15.325

	89.43

 ± 15.667

	F(1,40) = 0.077

p = 0.782

ηp2 = 0.002

	F(1,40) = 0.455

p = 0.504

ηp2 = 0.011

	F(1,40) = 2.757

p = 0.105

ηp2 = 0.064

	
 Glaucoma

N = 16

	86.550

 ± 10.993

	88.143

 ± 13.947

	
Saccade Duration (ms)	
 Control

N = 27

	154.341

 ± 39.113

	136.193

 ± 40.639

	F(1,40) = 1.462

p = 0.234

ηp2 = 0.035

	F(1,40) = 1.282

p = 0.264

ηp2 = 0.031

	F(1,40) = 0.669

p = 0.418

ηp2 = 0.016

	
 Glaucoma

N = 16

	146.749

 ± 27.504

	123.669

 ± 23.765

	
Saccade Frequency (saccades/s)	
 Control

N = 27

	1.696

 ± 0.384

	1.641

 ± 0.313

	F(1,40) = 0.436

p = 0.513

ηp2 = 0.011

	F(1,40) = 0.268

p = 0.608

ηp2 = 0.007

	F(1,40) = 0.011

p = 0.919

ηp2 = 0.000

	
 Glaucoma

N = 16

	1.744

 ± 0.354

	1.694

 ± 0.386

	
Saccade Amplitude (°)	
 Control

N = 27

	13.415

 ± 2.312

	10.448

 ± 2.353

	F(1,40) = 12.742

p < 0.001

ηp2 = 0.242

	F(1,40) = 2.210

p = 0.145

ηp2= 0.052

	F(1,40) = 1.001

p = 0.323

ηp2 = 0.024

	
 Glaucoma

N = 16

	12.119

 ± 3.453

	9.706

 ± 2.680

	
Fixation Duration (ms)	
 Control

N = 27

	246.807

 ± 31.467

	269.241

 ± 36.793

	F(1,40) = 5.272

p = 0.021

ηp2 = 0.125

	F(1,40) = 1.506

p = 0.227

ηp2 = 0.036

	F(1,40) = 0.000

p = 0.993

ηp2 = 0.000

	
 Glaucoma

N = 16

	269.188

 ± 69.902

	292.131

 ± 97.378

	
Fixation Frequency (fixation/s)	
 Control

N = 27

	2.1

 ± 0.253

	2.063

 ± 0.204

	F(1,40) = 2.103

p = 0.155

ηp2 = 0.05

	F(1,40) = 0.466

p = 0.499

ηp2 = 0.12

	F(1,40) = 0.049

p = 0.827

ηp2 = 0.001

	
 Glaucoma

N = 16

	2.144

 ± 0.299

	2.094

 ± 0.317

	
Significant differences are presented in bold.

Table 3 Means ± standard deviations of the eye tracking data during the “Trail-Walking-Test” of glaucoma patients and healthy sighted controls as well as the outcomes of the ANCOVA.

	One-way ANCOVA	
Group	
Performance (s)	
 Control

N = 28

	56.457

 ± 13.664

	F(1,42) = 0.416

p = 0.522, ηp2 = 0.010

	
 Glaucoma

N = 17

	59.440

 ± 14.384

	
Saccade Duration (ms)	
 Control

N = 28

	173.882

 ± 41.612

	F(1,42) = 3.320

p = 0.076, ηp2 0.073

	
 Glaucoma

N = 17

	152.847

 ± 35.770

	
Saccade Frequency (saccades/s)	
 Control

N = 28

	1.811

 ± 0.511

	F(1,42) = 0.120

p = 0.730, ηp2 = 0.003

	
 Glaucoma

N = 17

	1.759

 ± 0.433

	
Saccades Amplitude (°)	
 Control

N = 27

	12.186

 ± 2.287

	F(1,42) = 1.365

p = 0.249, ηp2 = 0.031

	
 Glaucoma

N = 16

	11.335

 ± 2.907

	
Fixation Duration (ms)	
 Control

N = 28

	205.921

 ± 32.859

	F(1,42) = 6.331

p = 0.016, ηp2 = 0.131

	
 Glaucoma

N = 17

	241.465

 ± 60.885

	
Fixation Frequency (fixation/s)	
 Control

N = 27

	2.164

 ± 0.352

	F(1,42) = 0.088

p = 0.768, ηp2 = 0.002

	
 Glaucoma

N = 16

	2.188

 ± 0.264

	
Significant differences are presented in bold.

Fig. 3 Means ± standard deviations and individual data for the fixation duration (A [p = 0.021]) and the saccade amplitude (B [p < 0.001]) during the “Speed-Court-Test” of all participants for the condition large screen (n = 49) and small screen (n = 49), and the fixation duration (C [p = 0.016]) during the “Trail-Walking-Test” of the glaucoma patients (n = 17) and healthy sighted controls (n = 28).

A significant SCREEN effect was found for fixation duration during the “Speed-Court-Test” (F (1,40) = 5.272, p = 0.021; ηp2 = 0.125). The post-hoc test indicated that the fixation duration was longer in the small screen compared to the large screen condition, irrespective of the group (p < 0.001). The secondary analysis revealed also a SCREEN effect (F (1,38) = 5.453, p = 0.025, ηp2 = 0.125). The post-hoc test indicated that the fixation duration was longer in the small screen compared to the large screen condition, irrespective of the group (p < 0.001). Furthermore, a significant SCREEN effect for saccade amplitude during the “Speed-Court-Test” was found (F (1,40) = 12.742, p < 0.001, ηp2 = 0.242). The post-hoc test indicated saccade amplitudes to be smaller for the small screen compared to the large screen condition, irrespective of the group (p < 0.001), see Fig. 3 and Table 2. The secondary analysis revealed also a SCREEN effect (F (1,38) = 12.617 p = 0.001, ηp2 = 0.249). The post-hoc test also indicated saccade amplitudes to be smaller for the small screen compared to the large screen condition, irrespective of the group (p < 0.001).

For the “Trail-Walking-Test” a significant GROUP effect was evident for fixation duration (F (1,42) = 6.331, p = 0.016, ηp2 = 0.131, mean difference = 35.536, 95% CI = 7.035—64.038). The fixation durations were longer in the glaucoma group than for the controls (see Fig. 3 and Table 3). The secondary analysis revealed also a GROUP effect (F (1,40) = 5.330, p = 0.026, ηp2 = 0.118, mean difference = 34.635, 95% CI = 4.315–64.955).

No significant correlations between gaze behavior, visuo-cognitive motor-task performance and visual performance (binocular VF mean deviation, better eye VF mean deviation, better eye pRNFL, better eye visual acuity, better eye dynamic visual acuity) in glaucoma patients were found.

Discussion

To the authors’ knowledge, the present study is the first investigating gaze behavior during visuo-cognitive-motor tasks with a change of direction in glaucoma patients and healthy sighted controls. The main findings were: (i) longer fixation durations in glaucoma patients during the “Trail-Walking-Test” and (ii) irrespective of group, longer fixation durations and smaller saccade amplitudes in the small- compared with large-screen condition during the “Speed-Court-Test”.

The findings from the present study revealed longer fixation durations during the “Trail-Walking-Test” in glaucoma patients compared with healthy sighted controls. Several studies reported conflicting results regarding the gaze behavior of glaucoma patients. For instance, glaucoma patients have been found to show a higher saccade and fixation frequency as well as shorter fixation duration compared to healthy sighted controls when watching driving scenes14. This was interpreted as a strategy to compensate for their VF loss. In contrast, the results of the real-world street crossing study from Cheong et al. indicate no difference between glaucoma patients and healthy sighted controls for saccades, but the authors have found a reduced fixation area and a different fixation distribution for the glaucoma patients13. The authors explained their findings with a reduction of the visual scanning area, which might have resulted in missing peripheral vision information during walking13. In accordance with the results of the present study, Lajoie et al. have also found that glaucoma patients showed a longer fixation duration while negotiating obstacles (vertical pole)18. This might be related to the fact that peripheral VF loss can cause glaucoma patients to rely more on central vision18. Of note, in the present study, a non-significant trend towards shorter saccade durations during the “Trail-Walking-Test” in glaucoma patients compared with healthy sighted controls was found (p = 0.076, ηp2 = 0.073). The longer fixation duration and the lower time to look for the next cone in advance might be a strategy to compensate for the VF loss18,34. Interestingly, despite these differences in the gaze behavior between groups, performance during the “Trail-Walking-Test” was not different between glaucoma patients and healthy sighted controls.

Furthermore, there were no between-group differences for the test performance and gaze behavior during the “Speed-Court-Test”, regardless of the factor SCREEN. This finding is in contrast to other studies that investigated visual search tasks in which the participants were not able to move their head. It has been found that glaucoma patients showed higher saccade frequency, fixation frequency, frequency duration, and saccadic velocity compared with healthy sighted controls14,35. Hence, in the present study, glaucomatous peripheral VF loss might have had no impact on gaze behavior because it might be compensated by head movements. Moreover, the group similarities in test performance and gaze behavior might be attributed to the mild stage of glaucoma progression in the patients of the present study.

It was assumed that glaucoma can be associated with cognitive dysfunction19, however, data of a previous study by our research group revealed no differences in cognitive test performance in the same glaucoma patients compared with healthy controls. This might be an explanation for the absence of group-differences in the glaucoma patients of this study36. Therefore, differences in gaze behavior between glaucoma patients and healthy sighted controls might dependent on other factors than cognitive function, e.g., type of task11. Regarding this, while the demands of the “Speed-Court-Test” did not appear to reveal differences in gaze behavior between glaucoma patients and healthy sighted controls, the “Trail-Walking-Test” might be suitable to mirror disease progression in mild stage of glaucoma. An assumption that deserves further attention in future studies.

The following limitations have to be considered in the present study. First, the tests were performed on 2 days, due to the duration of the entire testing protocol. This is less of a concern, given that this study design was chosen to avoid state fatigue37 induced by the testing procedure, which has been shown to influence gaze behavior38. As a second limitation, the environmental lightning condition was not fully standardized affecting scatter in the eye tracking data39. However, the observed group effects clearly exceeded this additional noise intrusion into the data. Third, due to the explorative nature of the analysis in the present study, no correction for multiple testing was applied.

In conclusion, the present study revealed a longer fixation duration during the “Trail-Walking-Test” in glaucoma patients, which might be a strategy to compensate for the VF loss. This gaze behavior might help to gather information about the environment to decrease the risk of falls. Furthermore, the longer fixation duration might serve as a biomarker for the effect of glaucoma on motor behavior, as reflected here by the oculo-motor behavior. However, given that performance and gaze behavior during the “Speed-Court-Test” was not different between the glaucoma patients and healthy sighted controls, group-differences seem to depend on the kind of visuo-cognitive-motor tasks.

Supported by funding of the German Research Foundation (DFG; #423926179) to MBH (HO-2002/20-1) & LS (SCHE 1584/5-1).

Author contributions

MH and LS contributed to conception and design of the study. CF, FS, GP, RB, and KA carried out the experiment. CF performed the data analysis. CF and MB contributed to the acquisition and interpretation of the data. CF contributed to the manuscirpt drafting with support from MB, RB, and LS. HT, MH, FS, GP, RB, KA contributed to the review of the final manuscript. All authors have read and approved the submitted version of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

Data are available on reasonable request to the corresponding author.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Michael B. Hoffmann and Lutz Schega.
==== Refs
References

1. Spaeth GL European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition Br. J. Ophthalmol. 2021 105 1 169 10.1136/bjophthalmol-2021-egsguidelines
Spaeth, G. L. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br. J. Ophthalmol. 105, 1–169. 10.1136/bjophthalmol-2021-egsguidelines (2021).10.1136/bjophthalmol-2021-egsguidelines
2. Steinmetz JD Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: an analysis for the Global Burden of Disease Study Lancet Glob. health 2021 9 e144 e160 10.1016/S2214-109X(20)30489-7 33275949
Steinmetz, J. D. et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob. health 9, e144–e160. 10.1016/S2214-109X(20)30489-7 (2021).33275949 10.1016/S2214-109X(20)30489-7
3. Tham Y-C Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis Ophthalmology 2014 121 2081 2090 10.1016/j.ophtha.2014.05.013 24974815
Tham, Y.-C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 121, 2081–2090. 10.1016/j.ophtha.2014.05.013 (2014).24974815 10.1016/j.ophtha.2014.05.013
4. Frezzotti P Structural and functional brain changes beyond visual system in patients with advanced glaucoma PLoS ONE 2014 9 e105931 10.1371/journal.pone.0105931 25162716
Frezzotti, P. et al. Structural and functional brain changes beyond visual system in patients with advanced glaucoma. PLoS ONE 9, e105931. 10.1371/journal.pone.0105931 (2014).25162716 10.1371/journal.pone.0105931
5. Crabb DP Smith ND Glen FC Burton R Garway-Heath DF How does glaucoma look?: Patient perception of visual field loss Ophthalmology 2013 120 1120 1126 10.1016/j.ophtha.2012.11.043 23415421
Crabb, D. P., Smith, N. D., Glen, F. C., Burton, R. & Garway-Heath, D. F. How does glaucoma look?: Patient perception of visual field loss. Ophthalmology 120, 1120–1126. 10.1016/j.ophtha.2012.11.043 (2013).23415421 10.1016/j.ophtha.2012.11.043
6. Schuster AK Erb C Hoffmann EM Dietlein T Pfeiffer N The diagnosis and treatment of glaucoma Deutsches Arzteblatt international 2020 117 225 234 10.3238/arztebl.2020.0225 32343668
Schuster, A. K., Erb, C., Hoffmann, E. M., Dietlein, T. & Pfeiffer, N. The diagnosis and treatment of glaucoma. Deutsches Arzteblatt international 117, 225–234. 10.3238/arztebl.2020.0225 (2020).32343668 10.3238/arztebl.2020.0225
7. Frezzotti P Giorgio A Toto F de Leucio A de Stefano N Early changes of brain connectivity in primary open angle glaucoma Hum. Brain Map. 2016 37 4581 4596 10.1002/hbm.23330
Frezzotti, P., Giorgio, A., Toto, F., de Leucio, A. & de Stefano, N. Early changes of brain connectivity in primary open angle glaucoma. Hum. Brain Map. 37, 4581–4596. 10.1002/hbm.23330 (2016).10.1002/hbm.23330
8. McDowell JE Dyckman KA Austin BP Clementz BA Neurophysiology and neuroanatomy of reflexive and volitional saccades: Evidence from studies of humans Brain Cogn. 2008 68 255 270 10.1016/j.bandc.2008.08.016 18835656
McDowell, J. E., Dyckman, K. A., Austin, B. P. & Clementz, B. A. Neurophysiology and neuroanatomy of reflexive and volitional saccades: Evidence from studies of humans. Brain Cogn. 68, 255–270. 10.1016/j.bandc.2008.08.016 (2008).18835656 10.1016/j.bandc.2008.08.016
9. Najjar RP Disrupted eye movements in preperimetric primary open-angle glaucoma Investig. Ophthalmol. Vis. Sci. 2017 58 2430 2437 10.1167/iovs.16-21002 28448671
Najjar, R. P. et al. Disrupted eye movements in preperimetric primary open-angle glaucoma. Investig. Ophthalmol. Vis. Sci. 58, 2430–2437. 10.1167/iovs.16-21002 (2017).28448671 10.1167/iovs.16-21002
10. Sparks DL The brainstem control of saccadic eye movements Nat. Rev. Neurosci. 2002 3 952 964 10.1038/nrn986
Sparks, D. L. The brainstem control of saccadic eye movements. Nat. Rev. Neurosci. 3(952), 964. 10.1038/nrn986 (2002).10.1038/nrn986
11. McDonald MA Stevenson CH Kersten HM Danesh-Meyer HV Eye movement abnormalities in glaucoma patients: A review Eye Brain 2022 14 83 114 10.2147/EB.S361946 36105571
McDonald, M. A., Stevenson, C. H., Kersten, H. M. & Danesh-Meyer, H. V. Eye movement abnormalities in glaucoma patients: A review. Eye Brain 14, 83–114. 10.2147/EB.S361946 (2022).36105571 10.2147/EB.S361946
12. Ramulu P Glaucoma and disability: Which tasks are affected, and at what stage of disease? Curr. Opin. Ophthalmol. 2009 20 92 98 10.1097/ICU.0b013e32832401a9 19240541
Ramulu, P. Glaucoma and disability: Which tasks are affected, and at what stage of disease?. Curr. Opin. Ophthalmol. 20, 92–98. 10.1097/ICU.0b013e32832401a9 (2009).19240541 10.1097/ICU.0b013e32832401a9
13. Cheong AMY Geruschat DR Congdon N Traffic gap judgment in people with significant peripheral field loss Optom. Vis. Sci. 2008 85 26 36 10.1097/OPX.0b013e31815ed6fd 18174838
Cheong, A. M. Y., Geruschat, D. R. & Congdon, N. Traffic gap judgment in people with significant peripheral field loss. Optom. Vis. Sci. 85, 26–36. 10.1097/OPX.0b013e31815ed6fd (2008).18174838 10.1097/OPX.0b013e31815ed6fd
14. Crabb DP Exploring eye movements in patients with glaucoma when viewing a driving scene PLoS ONE 2010 5 e9710 10.1371/journal.pone.0009710 20300522
Crabb, D. P. et al. Exploring eye movements in patients with glaucoma when viewing a driving scene. PLoS ONE 5, e9710. 10.1371/journal.pone.0009710 (2010).20300522 10.1371/journal.pone.0009710
15. Kasneci E Black AA Wood JM Eye-tracking as a tool to evaluate functional ability in everyday tasks in glaucoma J. Ophthalmol. 2017 2017 6425913 10.1155/2017/6425913 28293433
Kasneci, E., Black, A. A. & Wood, J. M. Eye-tracking as a tool to evaluate functional ability in everyday tasks in glaucoma. J. Ophthalmol. 2017, 6425913. 10.1155/2017/6425913 (2017).28293433 10.1155/2017/6425913
16. Sippel K Binocular glaucomatous visual field loss and its impact on visual exploration—A supermarket study PLoS ONE 2014 9 e106089 10.1371/journal.pone.0106089 25162522
Sippel, K. et al. Binocular glaucomatous visual field loss and its impact on visual exploration—A supermarket study. PLoS ONE 9, e106089. 10.1371/journal.pone.0106089 (2014).25162522 10.1371/journal.pone.0106089
17. Geruschat DR Hassan SE Turano KA Quigley HA Congdon NG Gaze behavior of the visually impaired during street crossing Optom. Vis. Sci. 2006 83 550 558 10.1097/01.opx.0000232219.23362.a6 16909081
Geruschat, D. R., Hassan, S. E., Turano, K. A., Quigley, H. A. & Congdon, N. G. Gaze behavior of the visually impaired during street crossing. Optom. Vis. Sci. 83, 550–558. 10.1097/01.opx.0000232219.23362.a6 (2006).16909081 10.1097/01.opx.0000232219.23362.a6
18. Lajoie K Miller AB Strath RA Neima DR Marigold DS Glaucoma-related differences in gaze behavior when negotiating obstacles Transl. Vis. Sci. Technol. 2018 7 10 10.1167/tvst.7.4.10 30050727
Lajoie, K., Miller, A. B., Strath, R. A., Neima, D. R. & Marigold, D. S. Glaucoma-related differences in gaze behavior when negotiating obstacles. Transl. Vis. Sci. Technol. 7, 10. 10.1167/tvst.7.4.10 (2018).30050727 10.1167/tvst.7.4.10
19. Arrigo A Cognitive dysfunctions in glaucoma: an overview of morpho-functional mechanisms and the impact on higher-order visual function Front. Aging Neurosci. 2021 13 747050 10.3389/fnagi.2021.747050 34690746
Arrigo, A. et al. Cognitive dysfunctions in glaucoma: an overview of morpho-functional mechanisms and the impact on higher-order visual function. Front. Aging Neurosci. 13, 747050. 10.3389/fnagi.2021.747050 (2021).34690746 10.3389/fnagi.2021.747050
20. Bartels T The SpeedCourt system in rehabilitation after reconstruction surgery of the anterior cruciate ligament (ACL) Arch. Orthop. Trauma Surg. 2016 136 957 966 10.1007/s00402-016-2462-4 27146667
Bartels, T. et al. The SpeedCourt system in rehabilitation after reconstruction surgery of the anterior cruciate ligament (ACL). Arch. Orthop. Trauma Surg. 136, 957–966. 10.1007/s00402-016-2462-4 (2016).27146667 10.1007/s00402-016-2462-4
21. Lissek VJ Ben Abdallah H Praetorius A Ohmann T Suchan B go4cognition: Combined physiological and cognitive intervention in mild cognitive impairment J. Alzheimer's Dis. 2022 89 449 462 10.3233/JAD-220145 35871331
Lissek, V. J., Ben Abdallah, H., Praetorius, A., Ohmann, T. & Suchan, B. go4cognition: Combined physiological and cognitive intervention in mild cognitive impairment. J. Alzheimer’s Dis. 89, 449–462. 10.3233/JAD-220145 (2022).35871331 10.3233/JAD-220145
22. Schott N Trail Walking Test zur Erfassung der motorisch-kognitiven Interferenz bei älteren Erwachsenen. Entwicklung und Überprüfung der psychometrischen Eigenschaften des Verfahrens Zeitschrift fur Gerontologie und Geriatrie 2015 48 722 733 10.1007/s00391-015-0866-3 25801510
Schott, N. Trail Walking Test zur Erfassung der motorisch-kognitiven Interferenz bei älteren Erwachsenen. Entwicklung und Überprüfung der psychometrischen Eigenschaften des Verfahrens. Zeitschrift fur Gerontologie und Geriatrie 48, 722–733. 10.1007/s00391-015-0866-3 (2015).25801510 10.1007/s00391-015-0866-3
23. Faul F Erdfelder E Lang A-G Buchner A G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences Behav. Res. Methods 2007 39 175 191 10.3758/bf03193146 17695343
Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175–191. 10.3758/bf03193146 (2007).17695343 10.3758/bf03193146
24. Frey I Berg A Grathwohl D Keul J Freiburger Fragebogen zur körperlichen Aktivität-Entwicklung, Prüfung und Anwendung. Sozial- und Praventivmedizin Sozial- und Praventivmedizin 1999 44 55 64 10.1007/BF01667127 10407953
Frey, I., Berg, A., Grathwohl, D. & Keul, J. Freiburger Fragebogen zur körperlichen Aktivität-Entwicklung, Prüfung und Anwendung. Sozial- und Praventivmedizin. Sozial- und Praventivmedizin 44, 55–64. 10.1007/BF01667127 (1999).10407953 10.1007/BF01667127
25. Tilscher H Gruber D Lembert S Raschner C Auswirkungen von Beeinträchtigungen am Bewegungsapparat auf das Ergebnis des S3-Körperstabilitätstests Manuelle Medizin 2007 45 409 414 10.1007/s00337-007-0558-1
Tilscher, H., Gruber, D., Lembert, S. & Raschner, C. Auswirkungen von Beeinträchtigungen am Bewegungsapparat auf das Ergebnis des S3-Körperstabilitätstests. Manuelle Medizin 45, 409–414. 10.1007/s00337-007-0558-1 (2007).10.1007/s00337-007-0558-1
26. Pastel S Comparison of gaze accuracy and precision in real-world and virtual reality Virtual Reality 2021 25 175 189 10.1007/s10055-020-00449-3
Pastel, S. et al. Comparison of gaze accuracy and precision in real-world and virtual reality. Virtual Reality 25, 175–189. 10.1007/s10055-020-00449-3 (2021).10.1007/s10055-020-00449-3
27. Hooge ITC Niehorster DC Hessels RS Benjamins JS Nyström M How robust are wearable eye trackers to slow and fast head and body movements? Behav. Res. Methods 2022 10.3758/s13428-022-02010-3 36326998
Hooge, I. T. C., Niehorster, D. C., Hessels, R. S., Benjamins, J. S. & Nyström, M. How robust are wearable eye trackers to slow and fast head and body movements?. Behav. Res. Methods10.3758/s13428-022-02010-3 (2022).36326998 10.3758/s13428-022-02010-3
28. Diamond A Executive functions Annu. Rev. Psychol. 2013 64 135 168 10.1146/annurev-psych-113011-143750 23020641
Diamond, A. Executive functions. Annu. Rev. Psychol. 64, 135–168. 10.1146/annurev-psych-113011-143750 (2013).23020641 10.1146/annurev-psych-113011-143750
29. Vickers AJ Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data BMC Med. Res. Methodol. 2005 5 35 10.1186/1471-2288-5-35 16269081
Vickers, A. J. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Med. Res. Methodol. 5, 35. 10.1186/1471-2288-5-35 (2005).16269081 10.1186/1471-2288-5-35
30. Wilcox RR Introduction to Robust Estimation and Hypothesis Testing 2017 4 Elsevier Science & Technology
Wilcox, R. R. Introduction to Robust Estimation and Hypothesis Testing 4th edn. (Elsevier Science & Technology, 2017).
31. Rasch D Guiard V The robustness of parametric statistical methods Psychol. Sci. 2004 46 175 208
Rasch, D. & Guiard, V. The robustness of parametric statistical methods. Psychol. Sci. 46, 175–208 (2004).
32. Lakens D Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs Front. Psychol. 2013 4 863 10.3389/fpsyg.2013.00863 24324449
Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front. Psychol. 4, 863. 10.3389/fpsyg.2013.00863 (2013).24324449 10.3389/fpsyg.2013.00863
33. Cohen J Statistical Power Analysis for the Behavioral Sciences 2013 Elsevier Science
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Elsevier Science, 2013).
34. Miller AB Lajoie K Strath RA Neima DR Marigold DS Coordination of gaze behavior and foot placement during walking in persons with glaucoma J. Glaucoma 2018 27 55 63 10.1097/IJG.0000000000000819 29117005
Miller, A. B., Lajoie, K., Strath, R. A., Neima, D. R. & Marigold, D. S. Coordination of gaze behavior and foot placement during walking in persons with glaucoma. J. Glaucoma 27, 55–63. 10.1097/IJG.0000000000000819 (2018).29117005 10.1097/IJG.0000000000000819
35. Martínez-Almeida Nistal I Lampreave Acebes P Martínez-de-la-Casa JM Sánchez-González P Validation of virtual reality system based on eye-tracking technologies to support clinical assessment of glaucoma Eur. J. Ophthalmol. 2021 31 3080 3086 10.1177/1120672120976047 33233935
Martínez-Almeida Nistal, I., Lampreave Acebes, P., Martínez-de-la-Casa, J. M. & Sánchez-González, P. Validation of virtual reality system based on eye-tracking technologies to support clinical assessment of glaucoma. Eur. J. Ophthalmol. 31, 3080–3086. 10.1177/1120672120976047 (2021).33233935 10.1177/1120672120976047
36. Freitag CW Behrens M Menrad T Al-Nosairy KO Stolle FH Prabhakaran GT Beyer R Thieme H Hoffmann MB Schega L Single- and dual-task gait performance in patientswith open-angle glaucoma: A cross-sectional study Transl. Vis. Sci. Technol. 2023 10.1167/tvst.0.0.5744 38015169
Freitag, C. W. et al. Single- and dual-task gait performance in patientswith open-angle glaucoma: A cross-sectional study. Transl. Vis. Sci. Technol.10.1167/tvst.0.0.5744 (2023).38015169 10.1167/tvst.0.0.5744
37. Behrens M Fatigue and human performance: An updated framework Sports Med. 2022 10.1007/s40279-022-01748-2 36258141
Behrens, M. et al. Fatigue and human performance: An updated framework. Sports Med.10.1007/s40279-022-01748-2 (2022).36258141 10.1007/s40279-022-01748-2
38. Zargari Marandi R Madeleine P Omland Ø Vuillerme N Samani A Eye movement characteristics reflected fatigue development in both young and elderly individuals Sci. Rep. 2018 8 13148 10.1038/s41598-018-31577-1 30177693
Zargari Marandi, R., Madeleine, P., Omland, Ø., Vuillerme, N. & Samani, A. Eye movement characteristics reflected fatigue development in both young and elderly individuals. Sci. Rep. 8, 13148. 10.1038/s41598-018-31577-1 (2018).30177693 10.1038/s41598-018-31577-1
39. Dunn MJ Minimal reporting guideline for research involving eye tracking (2023 edition) Behav. Res. Methods 2023 10.3758/s13428-023-02187-1 37697208
Dunn, M. J. et al. Minimal reporting guideline for research involving eye tracking (2023 edition). Behav. Res. Methods10.3758/s13428-023-02187-1 (2023).37697208 10.3758/s13428-023-02187-1
